← Back to Heartland Media Acquisition Stock
Heartland Media Acquisition (HMA) News
ATLANTA, July 24, 2023 (GLOBE NEWSWIRE) — Heartland Media Acquisition Corp. (“HMA” or the “Company”) (NYSE: HMA, HMA.U, HMA.WS) today announced that it should redeem all of its outstanding shares of Class A typical stock, par value $0.0001 per share (the “Public Shares”), effective as of the close of business on August 8, 2023, since […] The post Heartland Media Acquisition Corp. Publicizes Redemption of Public Shares and Subsequent Dissolution appeared first on TodaysStocks.com .
ATLANTA, July 24, 2023 (GLOBE NEWSWIRE) -- Heartland Media Acquisition Corp. (“HMA” or the “Company”) (NYSE: HMA, HMA.U, HMA.WS) today announced that it will redeem all of its outstanding shares of Class A common stock, par value $0.0001 per share (the “Public Shares”), effective as of the close of business on August 8, 2023, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (the “Charter”).
ATLANTA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Heartland Media Acquisition Corp. (NYSE: HMA.U) (the “Company”) today announced that on January 12, 2023, the Company received a notice letter (the “Notice”) from The New York Stock Exchange (the “NYSE”) indicating that the Company is not currently in compliance with the provision of Section 802.01B of the NYSE Listed Company Manual requiring the Company to maintain a minimum of 300 public stockholders on a continuous basis.
ATLANTA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Heartland Media Acquisition Corp. (NYSE: HMA.U) (the “Company”) today announced that on January 12, 2023, the Company received a notice letter (the “Notice”) from The New York Stock Exchange (the “NYSE”) indicating that the Company is not currently in compliance with the provision of Section 802.01B of the NYSE Listed Company Manual requiring the Company to maintain a minimum of 300 public stockholders on a continuous basis.
NAPLES, Fla.--(BUSINESS WIRE)--Health Management Associates, Inc. (NYSE: HMA) (“Issuer”) today announced the early results of the previously announced cash tender offers for any and all of its (i) $400 million outstanding principal amount of 6.125% Senior Notes due 2016 (CUSIP No. 421933AH5) (the “2016 Notes”) and (ii) $875 million outstanding principal amount of 7.375% Senior Notes due 2020 (CUSIP No. 421933AL6) (the “2020 Notes” and, together with the 2016 Notes, the “Notes”), as of 5:00 p.m., New York City time, January 23, 2014 (the “Consent Expiration” or “Withdrawal Time”), as well as the results of the previously announced consent solicitations with respect to the Notes, which expired at the Consent Expiration. As of the Consent Expiration, $370,288,000 aggregate principal amount, or approximately 92.6%, of the outstanding 2016 Notes and $854,088,000 aggregate principal amount, or approximately 97.6%, of the outstanding 2020 Notes have been validly tendered and not withdrawn, and the holders thereof have consented to the proposed amendments to the indenture governing the 2016 Notes (the “2016 Indenture”) and the indenture governing the 2020 Notes (the “2020 Indenture” and, together with the 2016 Notes, the “Indentures”) set forth in an Offer to Purchase and Consent Solicitation Statement (the “Offer to Purchase”), that was sent to holders of the Notes. Having received the requisite consents from the holders of Notes in connection with the consent solicitations, the Issuer intends to execute a supplemental indenture with respect to each of the Indentures (the “Supplemental Indentures”), which will eliminate substantially all of the covenants, certain default provisions applicable to the Notes and certain other provisions contained in each of the Indentures. The amendments contemplated by each Supplemental Indenture will not become operative until a majority in aggregate principal amount of the applicable series of Notes has been purchased by the Issuer pursuant to the terms of the tender offers, which is expected to occur on January 27, 2014. The following table sets forth the outstanding principal amount of Notes and the principal amount that has been tendered and not withdrawn as of the Consent Expiration: Aggregate Principal Amount Tenderedand Not Withdrawn Holders who validly tendered (and did not subsequently withdraw) their 2016 Notes prior to the Consent Expiration are eligible to receive the “Total Consideration” of $1,118.13 per $1,000 principal amount of the 2016 Notes, which includes a consent payment of $30.00 per $1,000 principal amount of the 2016 Notes. Holders who validly tendered (and did not subsequently withdraw) their 2020 Notes prior to the Consent Expiration are eligible to receive the “Total Consideration” of $1,161.88 per $1,000 principal amount of the 2020 Notes, which includes a consent payment of $30.00 per $1,000 principal amount of the 2020 Notes. These holders will also receive accrued and unpaid interest from the last interest payment on the applicable Notes up to, but not including, the payment date for such Notes accepted for purchase, which is expected to be January 27, 2014. The tender offers will expire at 11:59 p.m., New York City time, on February 6, 2014, unless extended or earlier terminated by the Issuer in its sole discretion (the “Expiration Time”). Holders who validly tender (and do not validly withdraw) their 2016 Notes after the Consent Expiration and prior to the Expiration Time will be entitled to receive consideration equal to $1,088.13 per $1,000 principal amount of the 2016 Notes. Holders who validly tender (and do not validly withdraw) their 2020 Notes after the Consent Expiration and prior to the Expiration Time will be entitled to receive consideration equal to $1,131.88 per $1,000 principal amount of the 2020 Notes. These holders will also receive accrued and unpaid interest on the Notes up to, but not including, the payment date for such Notes accepted for purchase, which is expected to be promptly after the Expiration Time. Holders of Notes tendered after the Consent Expiration will not receive a consent payment. Consummation of the tender offers and consent solicitations remains subject to the satisfaction or waiver of certain previously announced conditions including, but not limited to: (i) the consummation of the merger in which Issuer will survive as a direct or indirect wholly owned subsidiary of CHS/Community Health Systems, Inc., a Delaware corporation and wholly owned subsidiary of Community Health Systems, Inc., a Delaware corporation (“CHS”), which is expected to occur on January 27, 2014 (such merger, the “Merger”), (ii) the completion of certain debt financing transactions and availability of sufficient funds, (iii) the execution and delivery of the Supplemental Indentures and (iv) certain other conditions. Substantially concurrently with the closing of the Merger, the Issuer intends to irrevocably call for redemption all of the Notes that remain outstanding after the tender offers in accordance with the applicable Indenture. Prior to the completion of the redemptions, the Issuer will satisfy and discharge the Indentures governing the Notes by depositing the redemption prices in trust in accordance with the satisfaction and discharge provisions of the Indentures. The complete terms and conditions of the tender offers and consent solicitations are set forth in the Offer to Purchase and related Consent and Letter of Transmittal (“Letter of Transmittal”) that were sent to holders of the Notes. Copies of the Offer to Purchase and Letter of Transmittal may be obtained from the Tender and Information Agent for the tender offers and consent solicitations, D.F. King & Co. Inc., at (800) 290-6427 (toll-free). BofA Merrill Lynch and Credit Suisse are the Dealer Managers and Solicitation Agents for the tender offers and consent solicitations. Questions regarding the terms of the tender offers or consent solicitations may be directed to BofA Merrill Lynch at (888) 292-0070 (toll-free) and (980) 387-3907 (collect) and Credit Suisse at (800) 820-1653 (toll-free) and (212) 538-2147. This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The tender offers and consent solicitations are being made only by and pursuant to the terms of the Offer to Purchase and the related Letter of Transmittal. Holders are urged to read the Offer to Purchase and related documents carefully before making any decision with respect to the tender offers and consent solicitations. Holders of Notes must make their own decisions as to whether to tender their Notes and provide the related consents. None of Issuer, the Dealer Managers and Solicitation Agents or the Tender and Information Agent makes any recommendations as to whether holders should tender their Notes pursuant to the tender offers or provide the related consents, and no one has been authorized to make such a recommendation. The tender offers and consent solicitations are not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. Issuer expressly reserves the right, subject to applicable law, to terminate the tender offers and consent solicitations. This press release does not constitute a notice of redemption or an obligation to issue a notice of redemption in respect of the Notes. About HMA Health Management Associates, Inc., through its affiliates, owns and manages hospitals and ambulatory surgery centers in small cities and selected larger urban markets. HMA currently operates 71 hospitals in 15 states with approximately 11,000 licensed beds. Shares in Health Management Associates are traded on the New York Stock Exchange under the symbol “HMA.” Forward-Looking Statements Certain statements contained in this communication may constitute “forward-looking statements”. These statements include, but are not limited to, statements regarding the expected timing of the completion of the Merger, the benefits of the Merger, including future financial and operating results, the combined company’s plans, objectives, expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of CHS and Issuer and are subject to significant risks and uncertainties. Actual future events or results may differ materially from these statements. Such differences may result from the following factors: the ability to close the transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions, including the receipt of governmental approvals; the risk that the benefits of the transaction, including cost savings and other synergies may not be fully realized or may take longer to realize than expected; the impact of the transaction on third-party relationships; actions taken by either of the companies; changes in regulatory, social and political conditions, as well as general economic conditions. Additional risks and factors that may affect results are set forth in Issuer’s and CHS’s filings with the Securities and Exchange Commission, including each company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2012 or any Quarterly Report on Form 10-Q for a subsequent period, in each case as may be amended or supplemented. The forward-looking statements speak only as of the date of this communication. HMA does not undertake any obligation to update these statements.
FRANKLIN, Tenn. & NAPLES, Fla.--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE: CYH) (“CHS”) and Health Management Associates, Inc. (NYSE: HMA) (“HMA”) announced today that they have reached an agreement with the Federal Trade Commission (“FTC”) which will allow CHS to complete its acquisition of HMA. Under the terms of the agreement, CHS is required to divest two acute care facilities and related outpatient businesses currently owned by subsidiaries of HMA: Riverview Regional Medical Center, a 281-bed hospital located in Gadsden, Alabama, and Carolina Pines Regional Medical Center, a 116-bed hospital in Hartsville, South Carolina. CHS does not expect these divestitures to have a meaningful impact on the combined company’s financial operations or cost-savings. The completion of the HMA acquisition is not contingent on the immediate divestiture of these facilities, but the divestitures are required to be completed no later than six months after the FTC’s order is issued. Approval for CHS’s acquisition of HMA has also been received from the West Virginia Health Care Authority with respect to HMA’s facility in Williamson, West Virginia. The HMA acquisition is expected to be completed by the end of January 2014. Under the terms of the transaction, CHS will acquire each issued and outstanding share of the common stock of HMA for $10.50 in cash, 0.06942 of a share of CHS common stock, and a Contingent Value Right, which could yield additional cash consideration of up to $1.00 per share, depending on the outcome of certain litigation matters. About CHS Located in the Nashville, Tennessee, suburb of Franklin, Community Health Systems, Inc. is one of the largest publicly-traded hospital companies in the United States and a leading operator of general acute-care hospitals in non-urban and mid-size markets throughout the country. Through its subsidiaries, the Company currently owns, leases or operates 135 hospitals in 29 states with an aggregate of approximately 20,000 licensed beds. Its hospitals offer a broad range of inpatient and surgical services, outpatient treatment and skilled nursing care. In addition, through its subsidiary, Quorum Health Resources, LLC, the Company provides management and consulting services to non-affiliated general acute-care hospitals located throughout the United States. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” About HMA Health Management Associates, Inc., through its affiliates, owns and manages hospitals and ambulatory surgery centers in small cities and selected larger urban markets. HMA currently operates 71 hospitals in 15 states with approximately 11,000 licensed beds. Shares in Health Management Associates are traded on the New York Stock Exchange under the symbol “HMA.” Forward-Looking Statements Certain statements contained in this communication may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected timing of the completion of the merger, the benefits of the merger, including future financial and operating results, the combined company’s plans, objectives and expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of CHS and HMA and are subject to significant risks and uncertainties. Actual future events or results may differ materially from these statements. Such differences may result from the following factors: the ability to close the transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions; the risk that the benefits of the transaction, including cost savings and other synergies may not be fully realized or may take longer to realize than expected; the impact of the transaction on third-party relationships; actions taken by either of the companies; changes in regulatory, social and political conditions, as well as general economic conditions. Additional risks and factors that may affect results are set forth in HMA’s and CHS’s filings with the Securities and Exchange Commission, including each company’s most recent Annual Report on Form 10-K or Form 10-K/A and Quarterly Report on Form 10-Q or 10-Q/A. The forward-looking statements speak only as of the date of this communication. Neither CHS nor HMA undertakes any obligation to update these statements.
NAPLES, Fla.--(BUSINESS WIRE)--Health Management Associates, Inc. (NYSE: HMA) (“Issuer”) announced today that it has commenced cash tender offers for any and all of its (i) $400 million outstanding principal amount of 6.125% Senior Notes due 2016 (CUSIP No. 421933AH5) (the “2016 Notes”), and (ii) $875 million outstanding principal amount of 7.375% Senior Notes due 2020 (CUSIP No. 421933AL6) (the “2020 Notes” and, together with the 2016 Notes, the “Notes”). In conjunction with the tender offers, Issuer is soliciting consents to eliminate substantially all of the covenants, certain default provisions applicable to the Notes and certain other provisions contained in each of the indentures governing the Notes (the “Indentures”). On July 29, 2013, Issuer entered into an agreement and plan of merger, as amended on September 24, 2013 (as amended, the “Merger Agreement”), with Community Health Systems, Inc., a Delaware corporation (“CHS”), and FWCT-2 Acquisition Corporation, a Delaware corporation and wholly-owned subsidiary of CHS (“Merger Sub”). Pursuant to the terms of the Merger Agreement and subject to the satisfaction or waiver of certain conditions contained therein, Merger Sub, an entity formed by CHS for the sole purpose of effecting the transactions contemplated by the Merger Agreement, will be merged with and into Issuer. Issuer will survive the merger as a direct or indirect wholly owned subsidiary of CHS/Community Health Systems, Inc., a Delaware corporation and wholly-owned subsidiary of CHS (such merger, the “Merger”). CHS intends to consummate one or more debt financing transactions, so that Issuer, upon surviving the Merger as a direct or indirect subsidiary of CHS, will have sufficient funds, together with cash on hand, to pay the Total Consideration (as defined below) for all tendered Notes and delivered consents, accrued interest and all related fees and expenses (collectively, the “Financing Transaction”). The availability and terms of any financing transactions will be determined by market conditions and other factors at the time of any such transactions. The tender offers are scheduled to expire at 11:59 p.m., New York City time, on February 6, 2014, unless extended or earlier terminated (the “Expiration Time”). Holders who validly tender their Notes and provide their consents to the amendments to the applicable Indenture before 5:00 p.m., New York City time, on January 23, 2014, unless extended (the “Consent Expiration”), will be eligible to receive the Total Consideration, which includes a consent payment. Holders whose Notes are validly tendered and not withdrawn prior to the Consent Expiration and accepted for purchase will receive payment of the Total Consideration on the initial settlement date, which is currently expected to be January 24, 2014. Holders that validly tender their Notes after the Consent Expiration and prior to the Expiration Time will receive the Tender Offer Consideration (as defined below), plus accrued and unpaid interest, promptly after the Expiration Time. Tenders of Notes may be validly withdrawn and consents may be validly revoked until the Withdrawal Time (as defined below). With respect to the 2016 Notes, the “Total Consideration” for each $1,000 principal amount of 2016 Notes validly tendered and not validly withdrawn prior to the Consent Expiration is $1,118.13, which includes a consent payment of $30.00 per $1,000 principal amount of 2016 Notes. Holders of the 2016 Notes tendering after the Consent Expiration will be eligible to receive only the “Tender Offer Consideration,” which is $1,088.13 for each $1,000 principal amount of 2016 Notes validly tendered prior to the Expiration Time. With respect to the 2020 Notes, the “Total Consideration” for each $1,000 principal amount of 2020 Notes validly tendered and not validly withdrawn prior to the Consent Expiration is $1,161.88, which includes a consent payment of $30.00 per $1,000 principal amount of 2020 Notes. Holders of the 2020 Notes tendering after the Consent Expiration will be eligible to receive only the “Tender Offer Consideration,” which is $1,131.88 for each $1,000 principal amount of 2020 Notes validly tendered prior to the Expiration Time. Holders will also receive accrued and unpaid interest from the last interest payment on the applicable Notes up to, but not including, the applicable settlement date for all of such Notes that we accept for purchase in the tender offer. Tendered Notes may be withdrawn and consents may be revoked before 5:00 p.m., New York City time, on January 23, 2014, unless extended (the “Withdrawal Time”), but generally not afterwards. Any extension, termination or amendment of the tender offers will be followed as promptly as practicable by a public announcement thereof. Consummation of the tender offers and consent solicitations is subject to the satisfaction or waiver of certain conditions including, but not limited to: (i) the consummation of the Merger pursuant to the terms of the Merger Agreement, (ii) the completion of the Financing Transaction and availability of sufficient funds, (iii) the execution and delivery of supplemental indentures, and (iv) certain other conditions. The complete terms and conditions of the tender offers and consent solicitations are set forth in an Offer to Purchase and Consent Solicitation Statement (the “Offer to Purchase”) and related Consent and Letter of Transmittal (“Letter of Transmittal”) that are being sent to holders of the Notes. Copies of the Offer to Purchase and Letter of Transmittal may be obtained from the Tender and Information Agent for the tender offer and consent solicitation, D.F. King & Co. Inc., at (800) 290-6427 (toll-free). BofA Merrill Lynch and Credit Suisse are the Dealer Managers and Solicitation Agents for the tender offers and consent solicitations. Questions regarding the terms of the tender offers or consent solicitations may be directed to BofA Merrill Lynch at (888) 292-0070 (toll-free) and (980) 387-3907 (collect) and Credit Suisse at (800) 820-1653 (toll-free) and (212) 538-2147. This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The tender offers and consent solicitations are being made only by and pursuant to the terms of the Offer to Purchase and the related Letter of Transmittal. Holders are urged to read the Offer to Purchase and related documents carefully before making any decision with respect to the tender offers and consent solicitations. Holders of Notes must make their own decisions as to whether to tender their Notes and provide the related consents. None of Issuer, the Dealer Managers and Solicitation Agents or the Tender and Information Agent makes any recommendations as to whether holders should tender their Notes pursuant to the tender offers or provide the related consents, and no one has been authorized to make such a recommendation. The tender offers and consent solicitations are not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. Issuer expressly reserves the right, subject to applicable law, to terminate the tender offers and consent solicitations. This press release does not constitute a notice of redemption or an obligation to issue a notice of redemption in respect of the Notes. About HMA Health Management Associates, Inc., through its affiliates, owns and manages hospitals and ambulatory surgery centers in small cities and selected larger urban markets. HMA currently operates 71 hospitals in 15 states with approximately 11,000 licensed beds. Shares in Health Management Associates are traded on the New York Stock Exchange under the symbol “HMA.” Forward-Looking Statements Certain statements contained in this communication may constitute “forward-looking statements”. These statements include, but are not limited to, statements regarding the expected timing of the completion of the Merger, the benefits of the Merger, including future financial and operating results, the combined company’s plans, objectives, expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of CHS and Issuer and are subject to significant risks and uncertainties. Actual future events or results may differ materially from these statements. Such differences may result from the following factors: the ability to close the transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions, including the receipt of governmental approvals; the risk that the benefits of the transaction, including cost savings and other synergies may not be fully realized or may take longer to realize than expected; the impact of the transaction on third-party relationships; actions taken by either of the companies; changes in regulatory, social and political conditions, as well as general economic conditions. Additional risks and factors that may affect results are set forth in Issuer’s and CHS’s filings with the Securities and Exchange Commission, including each company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2012 or any Quarterly Report on Form 10-Q for a subsequent period, in each case as may be amended or supplemented. The forward-looking statements speak only as of the date of this communication. HMA does not undertake any obligation to update these statements.
FRANKLIN, Tenn. & NAPLES, Fla.--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE: CYH) (“CHS”) and Health Management Associates, Inc. (NYSE: HMA) (“HMA”) announced today that HMA stockholders voted to adopt the previously announced merger agreement under which CHS has agreed to acquire HMA. HMA stockholders approved the transaction with approximately 98.7 percent of the votes cast at today’s special meeting voting in favor of adoption of the merger agreement, representing approximately 81.7 percent of HMA’s outstanding common shares as of November 22, 2013, the record date for the special meeting. Steve Shulman, Chairman of the Board of Health Management Associates, said, “We are gratified that HMA stockholders have approved our merger with Community Health Systems and look forward to taking the steps necessary to complete the transaction.” Wayne T. Smith, Chairman of the Board, President and Chief Executive Officer of Community Health Systems, said, “We are pleased that HMA stockholders have seen the significant strategic value in combining with CHS. We are working now to finalize regulatory approvals, and we expect to complete this transaction quickly so that we can integrate our two companies and deliver on our plans for long-term growth and value creation.” The transaction is expected to be completed prior to the end of January 2014 and is subject to customary closing conditions, the receipt of regulatory approvals and the absence of certain adverse developments. About CHS Located in the Nashville, Tennessee, suburb of Franklin, Community Health Systems, Inc. is one of the largest publicly-traded hospital companies in the United States and a leading operator of general acute care hospitals in non-urban and mid-size markets throughout the country. Through its subsidiaries, CHS currently owns, leases or operates 135 hospitals in 29 states with an aggregate of approximately 20,000 licensed beds. Its hospitals offer a broad range of inpatient and outpatient medical and surgical services. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol "CYH." About HMA Health Management Associates, Inc., through its affiliates, owns and manages hospitals and ambulatory surgery centers in small cities and selected larger urban markets. HMA currently operates 71 hospitals in 15 states with approximately 11,000 licensed beds. Shares in Health Management Associates are traded on the New York Stock Exchange under the symbol “HMA.” Forward-Looking Statements Certain statements contained in this communication may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected timing of the completion of the merger, the benefits of the merger, including future financial and operating results, the combined company’s plans, objectives expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of CHS and HMA and are subject to significant risks and uncertainties. Actual future events or results may differ materially from these statements. Such differences may result from the following factors: the ability to close the transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions, including the receipt of governmental approvals; the risk that the benefits of the transaction, including cost savings and other synergies, may not be fully realized or may take longer to realize than expected; the impact of the transaction on third-party relationships; actions taken by either of the companies; changes in regulatory, social and political conditions, as well as general economic conditions. Additional risks and factors that may affect results are set forth in HMA’s and CHS’s filings with the Securities and Exchange Commission, including each company’s Annual Report on Form 10-K and Form 10-K/A for the fiscal year ending December 31, 2012. The forward-looking statements speak only as of the date of this communication. Neither CHS nor HMA undertakes any obligation to update these statements.
FRANKLIN, Tenn. & NAPLES, Fla.--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE: CYH) (“CHS”) and Health Management Associates, Inc. (NYSE: HMA) (“HMA”) announced today that the Registration Statement on Form S-4 relating to the companies' proposed merger has been declared effective by the Securities and Exchange Commission (“SEC”). The Form S-4 contains HMA’s definitive proxy statement relating to soliciting the required approval of the transaction by HMA stockholders. HMA is expected to commence the mailing of the definitive proxy statement to its stockholders on or about November 25, 2013. CHS and HMA encourage HMA stockholders to review the proxy statement and to vote FOR adoption of the merger agreement at the HMA special stockholders’ meeting to be held in Naples, Florida, at 8:00 a.m., local time, on January 8, 2014. “We are pleased that the SEC has completed its review, and we can continue to move towards the successful completion of our acquisition of HMA,” said Wayne T. Smith, chairman, president and chief executive officer of Community Health Systems, Inc. “We continue to believe this transaction represents full and fair value for HMA stockholders, while positioning CHS for long-term growth that will generate incremental stockholder value and benefit local communities and patients around the country. We look forward to working closely with HMA over the coming weeks to secure stockholder approval of the transaction.” The transaction is expected to be completed during the first quarter of 2014 and is subject to approval of HMA stockholders holding 70 percent of HMA’s outstanding shares, antitrust clearance, receipt of other regulatory approvals, and the absence of certain adverse developments. Under the terms of the transaction, CHS will acquire each issued and outstanding share of the common stock of HMA for $10.50 in cash, 0.06942 of a share of CHS common stock, and a Contingent Value Right, which could yield additional cash consideration of up to $1.00 per share, depending on the outcome of certain litigation matters described in the Registration Statement on Form S-4. On November 13, 2013, HMA announced that its Board of Directors unanimously recommended that HMA stockholders vote “FOR” the adoption of the merger agreement. Glenview Capital Management LLC, which owns approximately 14.3% of the common stock of HMA, also announced that it intends to vote “FOR” the adoption of the merger agreement at the special meeting of HMA stockholders. About CHS Located in the Nashville, Tennessee, suburb of Franklin, Community Health Systems, Inc. is one of the largest publicly-traded hospital companies in the United States and a leading operator of general acute care hospitals in non-urban and mid-size markets throughout the country. Through its subsidiaries, CHS currently owns, leases or operates 135 hospitals in 29 states with an aggregate of approximately 20,000 licensed beds. Its hospitals offer a broad range of inpatient and outpatient medical and surgical services. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” About HMA Health Management Associates, Inc., through its affiliates, owns and manages hospitals and ambulatory surgery centers in small cities and selected larger urban markets. HMA currently operates 71 hospitals in 15 states with approximately 10,782 licensed beds. Shares in Health Management Associates are traded on the New York Stock Exchange under the symbol “HMA.” Important Information and Where to Find It In connection with the proposed transaction, CHS has filed with the SEC a registration statement on Form S-4 that includes a proxy statement of HMA and a prospectus of CHS. The registration statement was declared effective by the SEC on November 22, 2013. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND DEFINITIVE PROXY STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT CHS, HMA AND THE MERGER. The definitive proxy statement/prospectus and a form of proxy will first be mailed to stockholders of HMA on or about November 25, 2013. These materials and other documents filed with the SEC will be available at no charge at the SEC’s website at www.sec.gov. In addition, stockholders will be able to obtain copies of the definitive proxy statement/prospectus and other documents filed with the SEC (when they become available) from CHS’s website at www.chs.net and HMA’s website at www.hma.com or by directing such request to CHS at 4000 Meridian Boulevard, Franklin, Tennessee 37067, Attention: Investor Relations, or to HMA at 5811 Pelican Bay Boulevard, Naples, Florida 34108, Attention: Investor Relations. CHS, HMA and certain of their respective directors, executive officers and other persons may be deemed to be participants in the solicitation of proxies in respect of the merger. Information regarding CHS’s directors and executive officers is available in CHS’s proxy statement filed with the SEC on April 5, 2013 in connection with its 2013 annual meeting of stockholders, and information regarding HMA’s directors and executive officers is available in (i) HMA’s proxy statement filed with the SEC on April 8, 2013 in connection with its 2013 annual meeting of stockholders and (ii) HMA’s consent revocation statement filed with the SEC on July 19, 2013 in response to the consent solicitation conducted by Glenview Capital Partners, L.P. and certain of its affiliates. Other information regarding persons who may be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the registration statement and proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Forward-Looking Statements Certain statements contained in this communication may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected timing of the completion of the merger, the benefits of the merger, including future financial and operating results, the combined company’s plans, objectives and expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of CHS and HMA and are subject to significant risks and uncertainties. Actual future events or results may differ materially from these statements. Such differences may result from the following factors: the ability to close the transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions, including the receipt of governmental approvals and the approval of HMA stockholders; the risk that the benefits of the transaction, including cost savings and other synergies, may not be fully realized or may take longer to realize than expected; the impact of the transaction on third-party relationships; actions taken by either of the companies; and changes in regulatory, social and political conditions, as well as general economic conditions. Additional risks and factors that may affect results are set forth in HMA’s and CHS’s filings with the Securities and Exchange Commission, including each company’s most recent Annual Report on Form 10-K or Form 10-K/A and Quarterly Report on Form 10-Q or 10 Q/A. The forward-looking statements speak only as of the date of this communication. Neither CHS nor HMA undertakes any obligation to update these statements.
NAPLES, Fla.--(BUSINESS WIRE)--Health Management Associates, Inc. (NYSE:HMA) (“HMA”) today announced that the Company’s Board of Directors, in consultation with its outside financial and legal advisors, has completed its comprehensive review of the definitive merger agreement, dated July 29, 2013, between HMA and Community Health Systems, Inc. (NYSE:CYH) (“CHS”) and has unanimously affirmed its support for the transaction. The Board recommends HMA stockholders vote “FOR” the adoption of the merger agreement with CHS at the Special Meeting of the Company’s stockholders to be scheduled. The Company noted that the merger agreement was previously unanimously approved by the Company’s former Board on July 29, 2013. Under the terms of the transaction, HMA will be acquired by CHS for approximately $7.6 billion, including the assumption of outstanding indebtedness. CHS will acquire each issued and outstanding share of the common stock of HMA for $10.50 in cash, 0.06942 of a share of CHS common stock and a Contingent Value Right, which could yield additional cash consideration of up to $1.00 per share, depending on the outcome of certain matters described in the Registration Statement on Form S-4 filed by CHS. HMA stockholders will own approximately 16 percent of the shares of the combined company following close of the transaction. “After conducting an extensive review in conjunction with our legal and financial advisors, we are confident that this transaction provides maximum value to HMA stockholders and represents the best path forward for the Company,” said Steve Shulman, Chairman of the Board. “In addition to having confidence in the value of the transaction, we also support the merger’s strategic rationale and benefits for HMA’s patients, physicians and Associates across the communities we serve. HMA and Community Health Systems are stronger together. The combined entity will be better positioned to address healthcare trends and challenges. In addition, the combined organization will have a greater local and regional market depth, expanded physician relations and physician footprint, and solid clinical operations infrastructure. The transaction remains on track to close during the first quarter of 2014, as scheduled, and we appreciate the patience of all our stakeholders as the Board conducted its review.” “We are excited to combine these two organizations to create a hospital company with more than 200 facilities and leverage our relative strengths and combined scale to better serve our patients, physicians and communities. We are pleased to have the full support of HMA’s new board of directors as we move forward to complete this transaction in the first quarter of 2014,” said Wayne T. Smith, Chairman, President and CEO of Community Health Systems. “This transaction will broaden our footprint into new geographic markets, allow us to form stronger networks and improve access to care, and strengthen our position for greater benefit and success under health care reform. All of which, when combined with expected meaningful synergies available to us through our infrastructure and systems, will enhance value for our shareholders, employees, physicians and the communities we serve. We look forward to continuing our work with HMA’s associates and physicians to ensure a smooth and effective transition.” Since the current Board was installed on August 16, 2013, it has met 11 times and conducted 18 committee meetings. The Board engaged Alvarez and Marsal Healthcare Industry Group, LLC (“A&M”) to conduct a comprehensive review of HMA’s operations, finance, and compliance. A&M’s analysis demonstrated, among other things, that a large initial investment would be necessary to build out HMA’s information and clinical capabilities, among other things, and a successive long road to incremental value would not outweigh the benefits of accepting CHS’s offer. The Board also engaged UBS Securities LLC (“UBS”) and Lazard Frères & Co. LLC (“Lazard”) to perform independent evaluations and analyses to formulate recommendations regarding the transaction with CHS. In connection with their evaluation and analyses, each of UBS and Lazard delivered an opinion to the Board of Directors that the consideration to be received by the Company’s stockholders in the transaction is fair, from a financial point of view, to our stockholders. The board also engaged Paul, Weiss, Rifkind, Wharton & Garrison, LLP as legal counsel. The Board has also taken actions to lead the organization while working within the terms of the merger agreement. The Board took the lead in overseeing the stability and performance of near-term operations, the retention of key talent in management, the preservation and strengthening of the consideration paid in the CHS proposal, the positive forward movement of HMA from a regulatory and compliance perspective, and the implementation of measures designed to increase transparency to shareholders. The parties continue to expect the transaction to close during the first quarter of 2014. The transaction is subject to satisfaction of customary closing conditions including approval of HMA’s stockholders holding 70 percent of HMA’s outstanding shares, antitrust clearance, receipt of other regulatory approvals and the absence of certain adverse developments. The Special Meeting of the Company’s stockholders to vote on the transaction will be scheduled in connection with the filing of a definitive proxy statement/prospectus by CHS and HMA. About HMA Health Management Associates, Inc., through its affiliates, owns and manages hospitals and ambulatory surgery centers in small cities and selected larger urban markets. HMA currently operates 71 hospitals in 15 states with approximately 11,000 licensed beds. Shares in Health Management Associates are traded on the New York Stock Exchange under the symbol “HMA.” Important Information and Where to Find It In connection with the proposed transaction, CHS has filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that includes a preliminary proxy statement of HMA and a preliminary prospectus of CHS. CHS and HMA plan to file a definitive proxy statement/prospectus and other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND DEFINITIVE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CHS, HMA AND THE MERGER. When completed and available, the definitive proxy statement/prospectus and a form of proxy will be mailed to stockholders of HMA. These materials and other documents filed with the SEC will be available at no charge at the SEC’s website at www.sec.gov. In addition, stockholders will be able to obtain copies of the definitive proxy statement/prospectus (when they become available) and other documents filed with the SEC from CHS’s website at www.chs.net or and HMA’s website at www.hma.com or by directing such request to CHS at 4000 Meridian Boulevard, Franklin, Tennessee 37067, Attention: Investor Relations, or to HMA at 5811 Pelican Bay Boulevard, Naples, Florida 34108, Attention: Investor Relations. CHS, HMA and certain of their respective directors, executive officers and other persons may be deemed to be participants in the solicitation of proxies in respect of the merger. Information regarding CHS’s directors and executive officers is available in CHS’s proxy statement filed with the SEC on April 5, 2013 in connection with its 2013 annual meeting of stockholders, and information regarding HMA’s directors and executive officers is available in HMA’s preliminary proxy statement contained in the registration statement on Form S-4 filed by CHS with the SEC on September 24, 2013, as may be amended. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Forward-Looking Statements Certain statements contained in this communication may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected timing of the completion of the merger, the benefits of the merger, including future financial and operating results, the combined company’s plans, objectives, expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of CHS and HMA and are subject to significant risks and uncertainties. Actual future events or results may differ materially from these statements. Such differences may result from the following factors: the ability to close the transaction on the proposed terms and within the anticipated time period, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions, including the receipt of governmental approvals; the risk that the benefits of the transaction, including cost savings and other synergies may not be fully realized or may take longer to realize than expected; the impact of the transaction on third-party relationships; actions taken by either of the companies; changes in regulatory, social and political conditions, as well as general economic conditions. Additional risks and factors that may affect results are set forth in HMA’s and CHS’s filings with the Securities and Exchange Commission, including each company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2012, as may be amended or supplemented. The forward-looking statements speak only as of the date of this communication. HMA does not undertake any obligation to update these statements.